The company is now up by 0.79% percent from yesterday’s close. Shares are trading at $176.00 which is marginally over the 50 day moving average which is $165.13 and which is well above the 200 day moving average of $146.80. The 50 day moving average went up by +6.58% and the 200 day average went up $29.20 or +19.89%.
Investors are more bearish on the company if you consider the rise in short interest. The firm had a rise in short interest from September 15, 2017 to September 29, 2017 of 7.90%. Short shares grew 118,677 over that timeframe. Days to cover increased from 5.0 to 6.0 and the percentage of shorted shares was 0.04% on September 29.
Here is a rundown on some insider market activity for ABIOMED, Inc. (NASDAQ:ABMD). Paul Thomas, Director reported the sale of 10,000 shares. The shares were sold on August 15th for an average price of $154.71. Thomas now owns $1,883,130 of the stock per the Form 4 SEC filing.
ABIOMED, Inc., launched on June 4, 1987, is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Business’s product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. Its products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons..
Here are a few substantial investment firms who have updated their positions. Balasa Dinverno & Foltz LLC reduced its ownership by shedding 245 shares a decrease of 9.4% in the quarter. Balasa Dinverno & Foltz LLC now holds 2,366 shares worth $399,000. The value of the position overall is up by 6.7%. Capital One, National Association bolstered its stake by buying 464 shares an increase of 22.8% as of 09/30/2017. Capital One, National Association currently owns 2,500 shares valued at $422,000. The total value of its holdings increased 44.5%.
As of the end of the quarter Central Trust Co had acquired a total of 180 shares growing its position 6.3%. The value of the total investment in ABIOMED, Inc. went from $409,000 to $512,000 a change of $103,000 quarter to quarter. State Treasurer State Of Michigan expanded its position by buying 49,000 shares an increase of 34.6% from 06/30/2017 to 09/30/2017. State Treasurer State Of Michigan claims 190,800 shares with a value of $32,169,000. The value of the position overall is up by 58.3%.
On October 16 the company was set at “Neutral” by BTIG Research down from the previous “Neutral” rating. Equity analyst SunTrust Robinson Humphrey issued its first research report on the stock by announcing an initial rating of “Buy”.
July 28 investment analysts at Leerink Swann maintained a stock rating of “Outperform” but raised the price expectation from $125.00 to $180.00.
ABIOMED, Inc.’s P/E ratio is 102.92 and the market cap of the company is 7.76B. In the last earnings report the EPS was $1.71 and is estimated to be $2.24 for the current year with 44,102,000 shares now outstanding. Analysts expect next quarter’s EPS to be $0.49 and the next full year EPS is anticipated to be $2.65.